Nasdaq GlobeNewswire

RedHill Biopharma Announces Closing of Concurrent Public Offering and Registered Direct Offering of its American Depositary Shares and Warrants and Partial Exercise of the Option of Underwriters

Del

TEL-AVIV, Israel, 2016-12-27 16:18 CET (GLOBE NEWSWIRE) --

RedHill Biopharma Ltd. (NASDAQ:RDHL) (TASE:RDHL) (“RedHill” or the “Company”), a biopharmaceutical company primarily focused on the development and commercialization of late clinical-stage, proprietary, orally-administered, small molecule drugs for gastrointestinal and inflammatory diseases and cancer, today announced the closing of its previously announced underwritten public offering and its concurrent registered direct offering of American Depositary Shares (“ADSs”) and warrants to purchase ADSs for aggregate gross proceeds, from both offerings combined, before deducting underwriting discounts and commissions, placement agent fees and other offering expenses, of approximately $38 million.

The underwritten public offering was for a total number of 2,250,000 ADSs, each representing ten of its ordinary shares, and warrants to purchase 1,125,000 ADSs, with gross proceeds of approximately $23 million. The concurrent registered direct offering was for a total number of 1,463,415 ADSs and warrants to purchase 731,708 ADSs with gross proceeds of approximately $15 million. Aggregate gross proceeds from both offerings combined totaled approximately $38 million.

The price in both offerings was $10.25 for a fixed combination of one ADS and a warrant to purchase 0.5 of an ADS. The warrants in both offerings have a per ADS exercise price of $13.33 and have a term of three years.

In addition, the Company announced that the underwriters exercised their option in part and purchased warrants to purchase 168,750 ADSs for a purchase price of $0.0047 per warrant. Following the partial exercise of the option by the underwriters, the underwriters have the 30-day option to purchase up to an additional 337,500 ADSs representing 3,375,000 ordinary shares. With this partial exercise, the number issued by the Company in the two offerings aggregates to a total of 3,713,415 ADSs, each representing ten of its ordinary shares, and warrants to purchase 2,025,458 ADSs.

Immediately following the closing of both the underwritten public offering and the registered direct offering, the number of outstanding ordinary shares of the Company is 164,974,234 (equivalent to approximately 16,497,423 ADS), excluding possible exercise of the warrants issued in either offering and excluding possible exercise by the underwriters of their option to purchase up to an additional 337,500 ADSs.

EMC2 Fund Ltd participated in the registered direct offering. Investors in the public offering included, among others, Sabby Management, LLC, DAFNA Capital Management, Rosalind Advisors, Inc., Koramic Holding, Lincoln Park Capital, Nexthera Capital LP and others.

Roth Capital Partners acted as the sole book-running manager and Echelon Wealth Partners acted as Canadian manager for the underwritten public offering with respect to sales in Canada.  Roth Capital Partners acted as placement agent in the registered direct offering.

The ADSs and warrants were issued pursuant to a shelf registration statement that was previously filed with, and declared effective by, the Securities and Exchange Commission (the “SEC”). A final prospectus supplement related to each of the offerings was filed with the SEC and is available on the SEC's website located at www.sec.gov.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such jurisdiction.

These offerings were made only by means of a prospectus. Copies of the final prospectus supplements and the accompanying prospectus relating to these offerings may be obtained, when available, by contacting Roth Capital Partners, Attention: Equity Capital Markets, 888 San Clemente Drive, Newport Beach, CA 92660, or by telephone at 800-678-9147, or by email at RothECM@roth.com.

About RedHill Biopharma Ltd.:
RedHill Biopharma Ltd. (NASDAQ:RDHL) (TASE:RDHL) is a biopharmaceutical company headquartered in Israel, primarily focused on the development and commercialization of late clinical-stage, proprietary, orally-administered, small molecule drugs for the treatment of gastrointestinal and inflammatory diseases and cancer. RedHill’s pipeline of proprietary products includes: (i) RHB-105 - an oral combination therapy for the treatment of Helicobacter pylori infection with successful results from a first Phase III study; (ii) RHB-104 - an oral combination therapy for the treatment of Crohn's disease with an ongoing first Phase III study and a completed proof-of-concept Phase IIa study for multiple sclerosis; (iii) BEKINDA® (RHB-102) - a once-daily oral pill formulation of ondansetron with an ongoing Phase III study for acute gastroenteritis and gastritis and an ongoing Phase II study for IBS-D; (iv) RHB-106 - an encapsulated bowel preparation licensed to Salix Pharmaceuticals, Ltd.; (v) YELIVA® (ABC294640)- a Phase II-stage, orally-administered, first-in-class SK2 selective inhibitor targeting multiple oncology, inflammatory and gastrointestinal indications; (vi) MESUPRON - a Phase II-stage first-in-class, orally-administered uPA inhibitor, targeting gastrointestinal and other solid tumors and (vii) RIZAPORT® (RHB-103) - an oral thin film formulation of rizatriptan for acute migraines, with a U.S. NDA currently under discussion with the FDA and marketing authorization received in Germany in October 2015. 

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements may be preceded by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential” or similar words. Forward-looking statements are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company’s control, and cannot be predicted or quantified and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, risks and uncertainties associated with (i) the initiation, timing, progress and results of the Company’s research, manufacturing, preclinical studies, clinical trials, and other therapeutic candidate development efforts; (ii) the Company’s ability to advance its therapeutic candidates into clinical trials or to successfully complete its preclinical studies or clinical trials; (iii) the extent and number of additional studies that the Company may be required to conduct and the Company’s receipt of regulatory approvals for its therapeutic candidates, and the timing of other regulatory filings, approvals and feedback; (iv) the manufacturing, clinical development, commercialization, and market acceptance of the Company’s therapeutic candidates; (v) the Company’s ability to establish and maintain corporate collaborations; (vi) the interpretation of the properties and characteristics of the Company’s therapeutic candidates and of the results obtained with its therapeutic candidates in research, preclinical studies or clinical trials; (vii) the implementation of the Company’s business model, strategic plans for its business and therapeutic candidates; (viii) the scope of protection the Company is able to establish and maintain for intellectual property rights covering its therapeutic candidates and its ability to operate its business without infringing the intellectual property rights of others; (ix) parties from whom the Company licenses its intellectual property defaulting in their obligations to the Company; (x) estimates of the Company’s expenses, future revenues capital requirements and the Company’s needs for additional financing (xi) competitive companies and technologies within the Company’s industry; and (xii) the impact of the political and security situation in Israel on the Company's business. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company's filings with the Securities and Exchange Commission (SEC), including the Company's Annual Report on Form 20-F filed with the SEC on February 26, 2015. All forward-looking statements included in this Press Release are made only as of the date of this Press Release. We assume no obligation to update any written or oral forward-looking statement unless required by law.

         Company contact:
         Adi Frish
         Senior VP Business Development & Licensing
         RedHill Biopharma
         +972-54-6543-112
         adi@redhillbio.com
         
         IR contact (U.S.):
         Marcy Nanus
         Senior Vice President
         The Trout Group
         +1-646-378-2927
         Mnanus@troutgroup.com

Om Nasdaq GlobeNewswire

Nasdaq GlobeNewswire
Nasdaq GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

+1 212 401 8700http://www.nasdaqomx.com

NASDAQ (NASDAQ: NDAQ) is a leading provider of trading, exchange technology, information and public company services across six continents.

Følg saker fra Nasdaq GlobeNewswire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Nasdaq GlobeNewswire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Nasdaq GlobeNewswire

Vricon's disruptive 3D GEOINT technology fuels company growth18.6.2018 22:23Pressemelding

Company's momentum reflects growing need for high-resolution, extremely accurate 3D data and solutions McLean, VA, June 18, 2018 (GLOBE NEWSWIRE) -- Vricon, a global leader in 3D data and solutions, today announced that it has more than doubled its year-over-year sales growth rate and set a record pace for new customer acquisition. Vricon serves the global professional geospatial market with world-leading 3D geodata and 3D visualization solutions. With direct access to the world's largest global imagery archive, Vricon uses automated 3D image-processing algorithms inside a state-of-the-art high-performance computing environment to produce its high-resolution 3D data and solutions for government and commercial clients. Use of 3D geodata helps users to see the world as it really exists, explain what they're seeing more clearly, and better convey their findings to decision makers. Vricon has greatly increased and diversified its government-sector portfolio. From early 2017 to today, Vrico

Cloudian wins Cloud Company of the Year at the 2018 UK Storage Awards18.6.2018 19:05Pressemelding

SAN MATEO, Calif. and LONDON, June 18, 2018 (GLOBE NEWSWIRE) -- Cloudian, the innovation leader in enterprise object storage systems, today announced that it has been awarded "Cloud Company of the Year 2018" at the UK Storage Awards. The win, which builds on its win as "Enterprise Hybrid Storage Product of the Year" at the 2017 ceremony, comes as Cloudian achieves record-breaking year-on-year success and growth across EMEA. The Storage Awards mark one of the biggest award nights in the storage industry, recognising IT's most innovative leaders and rewarding those that make significant contributions to the industry. Attended by global companies of all sizes, the ceremony took place at The Tower Hotel in London. Peers, partners and clients took part in a round of voting to select the deserving winners - with a record number of votes cast. This year, Cloudian walked away as "Cloud Company of the Year 2018," awarded for its innovative contributions to the cloud computing world. Throughout

Raven Indusries Releases CR12(TM) Field Computer18.6.2018 16:49Pressemelding

12-Inch Display With Field Planning Features Helps Farmers Save Time and Increase Efficiencies MIDDENMEER, The Netherlands, June 18, 2018 (GLOBE NEWSWIRE) -- Raven Industries (NASDAQ:RAVN) announced today the release of a new, larger field computer: the CR12(TM). Utilizing the same powerful functionality as the CR7(TM) field computer, the CR12 offers an extensive field planning feature for increased efficiencies. Built with a durable magnesium waterproof housing and a full glass capacitive touchscreen with high brightness, the CR12 also boasts a wider, 12.1-inch display. The CR12 joins the CR7 as the latest field computer in the CRX display family. This powerful operating system features easy job set-up, fewer touches and greater efficiencies - empowering the user with extraordinary data management capabilities. A simple widget concept, easily accessible settings, and ISO Universal Terminal and Task Controller capabilities make this mighty unit an affordable, plug-and-play system. Like

FPGA programming solution goes live at AEE 2018 in latest version of SLX18.6.2018 15:00Pressemelding

Silexica / FPGA programming solution goes live at AEE 2018 in latest version of SLX . Processed and transmitted by Nasdaq Corporate Solutions. The issuer is solely responsible for the content of this announcement. Industry-first solution fully explores the design space to optimize hardware/software partitioning SLX automatically inserts pragmas and rewrites code to make it High-Level Synthesis (HLS) ready Solution designed in collaboration with customers including Ricoh SAN JOSE, Calif. and COLOGNE, Germany, June 18, 2018 (GLOBE NEWSWIRE) -- Silexica will launch a new solution within SLX to support the increasing use of FPGAs for embedded computing tasks such as sensor fusion and deep learning. It has been developed in partnership with Ricoh and other customers who will use the solution for industrial automation and defense projects. The technology will be presented at Silexica's first appearance one of the world's biggest avionics exhibitions - AEE held in Munich from June 19-20. The

Goldman Sachs and Cisco to Host Tech Talk on Data Center Networking18.6.2018 14:00Pressemelding

SAN JOSE, Calif., June 18, 2018 (GLOBE NEWSWIRE) -- Cisco will host a conference call with Goldman Sachs and Cisco's Ish Limkakeng, SVP, Product Management, Data Center Networking Group. The discussion will focus on Cisco's data center networking strategy, comprehensive portfolio, and its competitive advantage as customers seek highly secure and differentiated offerings. Interested parties can find more information on Cisco's Investor Relations website at https://investor.cisco.com. No new financial information will be discussed on this conference call. Date: Thursday, June 21, 2018 Time: 8:30 am PT / 11:30 am ET Speaker: Ish Limkakeng, SVP, Product Management, Data Center Networking Group Moderator: Goldman Sachs' Rod Hall, Managing Director Participant Dial in: Toll Free: 877-208-2954 International Number: 973-528-0056 Passcode: 201872 Replay Information (available until July 5, 2018): Toll Free: 800-332-6854 International Number: 973-528-0005 Passcode: 201872 This event will be webc

DSM Sinochem Pharmaceuticals launches Atorvastatin film-coated tablets, expanding its finished dosage statins portfolio18.6.2018 11:23Pressemelding

Rijswijk, 18 June 2018, June 18, 2018 (GLOBE NEWSWIRE) -- Building upon its first generic finished dosage statin launch (Rosuvastatin) in January of this year, DSM Sinochem Pharmaceuticals (DSP) has this month released its fully backward-integrated, generic Atorvastatin drug product within the EU. Additional markets are scheduled to follow later in the year.Atorvastatin is used primarily in the prevention of cardiovascular disease and hyperlipidemia, commonly known as high cholesterol, the number one cause of death worldwide. Currently, statins are the most prescribed drug family globally in the fight against these potentially life-threatening conditions. Expanding statins portfolio With the launch now of Atorvastatin finished dosage formulation, coming on the heels of the successful launch of Rosuvastatin in January of 2018, DSP is actively expanding its statins drug product portfolio, realizing its aspiration of becoming a full-service generics pharmaceutical company. What sets DSP a

I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.

Besøk vårt presserom